Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, Its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma

Allogene Therapeutics, Inc. announced that the US FDA has granted orphan-drug designation to ALLO-605, the Company’s next-generation AlloCAR T product candidate targeting BCMA for the treatment of multiple myeloma.
[Allogene Therapeutics, Inc.]
Press Release